CR11572A - Derivados del acido fenilacetico como moduladores de la inflamacion - Google Patents

Derivados del acido fenilacetico como moduladores de la inflamacion

Info

Publication number
CR11572A
CR11572A CR11572A CR11572A CR11572A CR 11572 A CR11572 A CR 11572A CR 11572 A CR11572 A CR 11572A CR 11572 A CR11572 A CR 11572A CR 11572 A CR11572 A CR 11572A
Authority
CR
Costa Rica
Prior art keywords
derivatives
modulators
inflammation
phenylacetic acid
compounds
Prior art date
Application number
CR11572A
Other languages
English (en)
Inventor
Mark Grillo
An-Rong Li
Jiwen Liu
Julio C Medina
Yongli Su
Yingcai Wang
Janan Jona
Alan Allgeier
Jacqueline Milne
Jerry Murry
Joseph F Payack
Thomas Storz
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CR11572A publication Critical patent/CR11572A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Se proporcionan compuestos, composiciones farmaceuticas y metodos que son de utilidad para tratar enfermedades y afecciones inflamatorias e inmunes. en particular, la invencion proporciona compuestos que modulan la funcion y/o la expresion de proteinas implicadas en enfermedades atopicas, afecciones de origen inflamatorio y cancer. Los compuestos de interes son derivados del acido carboxilico.
CR11572A 2007-12-19 2010-07-19 Derivados del acido fenilacetico como moduladores de la inflamacion CR11572A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US843307P 2007-12-19 2007-12-19

Publications (1)

Publication Number Publication Date
CR11572A true CR11572A (es) 2010-08-13

Family

ID=40564868

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11572A CR11572A (es) 2007-12-19 2010-07-19 Derivados del acido fenilacetico como moduladores de la inflamacion

Country Status (20)

Country Link
US (1) US8183293B2 (es)
EP (1) EP2231595B1 (es)
JP (1) JP5437267B2 (es)
KR (1) KR20100102668A (es)
CN (1) CN101903338A (es)
AR (1) AR071279A1 (es)
AU (1) AU2008343924B2 (es)
BR (1) BRPI0821197A2 (es)
CA (1) CA2707789A1 (es)
CL (1) CL2008003832A1 (es)
CO (1) CO6321234A2 (es)
CR (1) CR11572A (es)
EA (1) EA201001029A1 (es)
ES (1) ES2471919T3 (es)
IL (1) IL206069A0 (es)
MA (1) MA32013B1 (es)
PE (1) PE20091526A1 (es)
TN (1) TN2010000223A1 (es)
TW (1) TW200940051A (es)
WO (1) WO2009085177A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
CN104114169A (zh) 2011-12-16 2014-10-22 阿托佩斯治疗有限公司 用于治疗嗜酸细胞性食管炎的crth2拮抗剂和质子泵抑制剂的组合物
US9974759B2 (en) * 2013-05-31 2018-05-22 Indiana University Research And Technology Corporation Beta 2 adrenoceptor antagonists for treating orthostatic hypotension
JP6770522B2 (ja) * 2015-02-13 2020-10-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 全身性エリテマトーデスを予防し、及び／又は、治療するためのｐｔｇｄｒ−１及び／又はｐｔｇｄｒ−２アンタゴニスト
US9840481B2 (en) 2016-03-22 2017-12-12 Merck Sharp & Dohme Corp. Allosteric modulators of nicotinic acetylcholine receptors
ES2733477T3 (es) * 2017-07-04 2019-11-29 Fis Fabbrica Italiana Sintetici Spa Procedimiento eficaz para la preparación de sitagliptina a través de una preparación muy eficaz del intermedio ácido 2,4,5-trifluorofenilacético

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8704158D0 (en) 1987-02-23 1987-04-01 Wellcome Found Substituted hydantoin compounds
US5849780A (en) 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
JP3894949B2 (ja) 1993-06-30 2007-03-22 ザ、ウェルカム、ファンデーション、リミテッド 抗アテローム性動脈硬化症ジアリール化合物
US5545669A (en) 1994-06-02 1996-08-13 Adams; Jerry L. Anti-inflammatory compounds
NZ297774A (en) * 1994-12-20 1998-10-28 Hoffmann La Roche Aryl and heteroaryl sulphonamide derivatives; preparation and medicaments
US6008234A (en) * 1996-09-12 1999-12-28 Berlex Laboratories, Inc. Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants
CA2264521A1 (en) 1996-09-12 1998-03-19 Schering Aktiengesellschaft Benzamidine derivatives substituted by cyclic amino acid or cyclic hydroxy acid derivatives and their use as anti-coagulants
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
JPH11202458A (ja) 1998-01-16 1999-07-30 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
US5929250A (en) 1997-01-23 1999-07-27 Smithkline Beecham Corporation IL-8 receptor antagonists
EP1076641A1 (en) 1998-04-29 2001-02-21 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
AR023659A1 (es) 1998-09-18 2002-09-04 Vertex Pharma Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos
US6248739B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
WO2000051971A1 (en) 1999-03-01 2000-09-08 Pfizer Products Inc. Oxamic acids and derivatives as thyroid receptor ligands
DE60020226T2 (de) 1999-03-10 2006-02-02 Shionogi & Co., Ltd. Medizinische zubereitungen mit [2.2.1] und [3.1.1]bicycloskelett die antagonisten für sowohl pgd 2? als auch txa 2? rezeptoren sind
ATE315230T1 (de) 1999-08-23 2006-02-15 Bml Inc Verfahren zum identifizieren von prostaglandin d2 rezeptor modulatoren
US6531291B1 (en) * 1999-11-10 2003-03-11 The Trustees Of Columbia University In The City Of New York Antimicrobial activity of gemfibrozil and related compounds and derivatives and metabolites thereof
AU2001236605A1 (en) 2000-02-01 2001-08-14 Cor Therapeutics, Inc. Indole and benzimidazole inhibitors of factor xa
US20010047027A1 (en) 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
JPWO2001094309A1 (ja) 2000-06-02 2004-02-05 塩野義製薬株式会社 Ｐｇｄ２／ｔｘａ２両受容体拮抗性医薬組成物
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
AU2002229611A1 (en) 2000-12-08 2002-06-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of active compounds capable of modulating the intracellular pathway triggered by the dp receptor in langerhans cells
WO2002051805A1 (de) 2000-12-27 2002-07-04 Bayer Aktiengesellschaft Indol-derivate
DE60215000T2 (de) 2001-05-23 2007-08-09 Merck Frosst Canada & Co, Kirkland Dihydropyrroloil[1,2-a]indol- und Tetrahydropyridol[1,2-a]indol-Derivate als Prostaglandin-D2-Rezeptor-Antagonisten
MXPA04001253A (es) 2001-08-09 2004-06-03 Ono Pharmaceutical Co Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo.
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
CN100378083C (zh) 2002-03-19 2008-04-02 小野药品工业株式会社 羧酸化合物和含有所述化合物作为活性成分的药物制剂
WO2003097042A1 (en) 2002-05-16 2003-11-27 Shionogi & Co., Ltd. Pgd2 receptor antagonist
EP2423190A1 (en) 2002-05-16 2012-02-29 Shionogi&Co., Ltd. Compounds Exhibiting PGD 2 Receptor Antagonism
GB2388540A (en) 2002-05-17 2003-11-19 Bayer Ag New use of Ramatroban
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
GB0224557D0 (en) 2002-10-22 2002-11-27 Glaxo Group Ltd Novel compounds
ES2401079T3 (es) * 2002-12-20 2013-04-16 Amgen Inc. Moduladores del asma y de la inflamación alérgica
WO2005054176A1 (en) 2003-11-25 2005-06-16 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
EP1937632A1 (en) * 2005-10-06 2008-07-02 Astra Zeneca AB Novel compounds
JP5069752B2 (ja) * 2006-12-15 2012-11-07 グラクソ グループ リミテッド Ｅｐ４受容体アゴニストとしてのベンズアミド誘導体
US7960567B2 (en) * 2007-05-02 2011-06-14 Amgen Inc. Compounds and methods useful for treating asthma and allergic inflammation
WO2011014587A2 (en) 2009-07-31 2011-02-03 Amira Pharmaceuticals, Inc. Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
JP2013500979A (ja) 2009-07-31 2013-01-10 パンミラ ファーマシューティカルズ，エルエルシー． Ｄｐ２受容体アンタゴニストの皮膚用製剤

Also Published As

Publication number Publication date
ES2471919T3 (es) 2014-06-27
CN101903338A (zh) 2010-12-01
AU2008343924A2 (en) 2011-02-17
TW200940051A (en) 2009-10-01
BRPI0821197A2 (pt) 2015-06-16
US20090275659A1 (en) 2009-11-05
PE20091526A1 (es) 2009-11-01
EA201001029A1 (ru) 2011-06-30
EP2231595A1 (en) 2010-09-29
US8183293B2 (en) 2012-05-22
CA2707789A1 (en) 2009-07-09
TN2010000223A1 (en) 2011-11-11
EP2231595B1 (en) 2014-04-23
KR20100102668A (ko) 2010-09-24
WO2009085177A1 (en) 2009-07-09
AU2008343924B2 (en) 2013-01-17
AU2008343924A1 (en) 2009-07-09
AR071279A1 (es) 2010-06-09
CO6321234A2 (es) 2011-09-20
IL206069A0 (en) 2010-11-30
CL2008003832A1 (es) 2010-03-26
JP5437267B2 (ja) 2014-03-12
MA32013B1 (fr) 2011-01-03
JP2011507847A (ja) 2011-03-10

Similar Documents

Publication Publication Date Title
CY1123958T1 (el) Μεθοδος παρασκευης παραγωγων και ενδιαμεσων καρβαμοϋλπυριδονης
CY1120390T1 (el) Συνθεση και μεθοδος για διαγνωση και θεραπεια ασθενειων που σχετιζονται με εκφυλισμο νευριτων
CY1121299T1 (el) Υποκατεστημενες τρικυκλικες ενωσεις ως αναστολεις fgfr
CY1124024T1 (el) Νεες ctla4-ig ανοσοπροσκολλητινες
DOP2019000287A (es) Anticuerpos monoclonales contra el inhibidor de la vía del factor tisular (tfpi)
CY1117956T1 (el) N3-αντικατεστημενα-n1-sulfonyl-5-fluoropyrimidinone παραγωγα
DOP2012000257A (es) Derivados del acido 1-amino-2-ciclopropiletilboronico
CY1119762T1 (el) C-17-ετεροαρυλικα παραγωγα ελαιολικου οξεος και μεθοδοι χρησης αυτων
MX373141B (es) Anticuerpos anti-homologo relacionado con las convulsiones 6 (anti-sez6) y metodos de uso.
PE20160538A1 (es) Anticuerpos monoclonales optimizados contra el inhibidor de la via del factor tisular (tfpi)
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
CY1116424T1 (el) Παραγωγο αδενινης ως αναστολεας ρι3κ
MX2016017296A (es) Sintasa del acido cannabicromenico proveniente de cannabis sativa.
UY35023A (es) Derivados c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso
GT201400034A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
CY1115588T1 (el) Αναστολεις ανθρωπινης πρωτεϊνικης φωσφατασης τυροσινης-β και η φαρμακευτικη χρηση τους
MX393494B (es) Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr).
GT201200153A (es) Derivados del ácido carbamoil-metil-amino-acético sustituido como inhibidores de nep novedosos
EA201491817A1 (ru) Терапевтическое применение продуктов из косточек винограда шардоне
GT201200171A (es) Derivados de fenilimidazol heteroaromáticos como inhibidores de enzima pde10a
CO6321234A2 (es) Derivados de acido fenilacetico como moduladores de la inflamacion
MX2015003701A (es) Composiciones para tratamiento.
UA117353C2 (uk) Форми дозування ензалутаміду
ECSP12011837A (es) Derivados de pirazol que modulan la estearoil-coa-desaturasa
CY1123044T1 (el) Νεες ενωσεις

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)